Overview:

Summary

Global Markets Direct’s, 'Congenital Heart Disease - Pipeline Review, Q2 2011', provides an overview of the Congenital Heart Disease therapeutic pipeline. This report provides information on the therapeutic development for Congenital Heart Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congenital Heart Disease. 'Congenital Heart Disease - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Congenital Heart Disease.
- A review of the Congenital Heart Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Congenital Heart Disease pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Congenital Heart Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Congenital Heart Disease pipeline depth and focus of Congenital Heart Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Congenital Heart Disease Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Congenital Heart Disease 9
Congenital Heart Disease Therapeutics under Development by Companies 11
Congenital Heart Disease Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Congenital Heart Disease Therapeutics - Products under Development by Companies 18
Congenital Heart Disease Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Congenital Heart Disease Therapeutics Development 20
Mesoblast Ltd 20
CSL Limited 20
Genetrix SL 21
Asklepion Pharmaceuticals, LLC. 21
Congenital Heart Disease - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Human Plasma-Derived Factor XIII Concentrate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Citrulline - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Spironolactone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Phenoxybenzamine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Enalapril - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Nitric Oxide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Citrupress IV - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Hydrocortisone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Pentoxifylline - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Indomethacin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IVIG - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tadalafil - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Stromal-derived factor 1 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Indomethcin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Tracleer - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ibuprofen - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Ctx101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Paracetamol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Autologous Cardiac Progenitor Cell Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Congenital Heart Disease Therapeutics – Drug Profile Updates 46
Congenital Heart Disease Therapeutics - Discontinued Products 47
Congenital Heart Disease - Featured News 48
Feb 06, 2009: PLx Receives $0.73 Million In Funding From US Army In SBIR Phase II Award 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 50
Contact Us 50
Disclaimer 50"

List of Tables
Number of Products Under Development for Congenital Heart Disease, Q2 2011 9
Products under Development for Congenital Heart Disease – Comparative Analysis, Q2 2011 10
Number of Products under Development by Companies, Q2 2011 11
Number of Products under Investigation by Universities/Institutes, Q2 2011 13
Comparative Analysis by Late Stage Development, Q2 2011 14
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 15
Comparative Analysis by Early Clinical Stage Development, Q2 2011 16
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 17
Products under Development by Companies, Q2 2011 18
Products under Investigation by Universities/Institutes, Q2 2011 19
Mesoblast Ltd, 2011 20
CSL Limited, 2011 20
Genetrix SL, 2011 21
Asklepion Pharmaceuticals, LLC., 2011 21
Assessment by Monotherapy Products, Q2 2011 22
Assessment by Stage and Route of Administration, Q2 2011 24
Assessment by Molecule Type, Q2 2011 26
Congenital Heart Disease Therapeutics – Drug Profile Updates 46
Discontinued Products 47"

List of Figures
Number of Products under Development for Congenital Heart Disease, Q2 2011 9
Products under Development for Congenital Heart Disease – Comparative Analysis, Q2 2011 10
Products under Development by Companies, Q2 2011 11
Products under Investigation by  Universities/Institutes, Q2 2011 12
Late Stage Products, Q2 2011 14
Mid Clinical Stage Products, Q2 2011 15
Early Clinical Stage Products, Q2 2011 16
Pre-Clinical Stage Products, Q2 2011 17
Assessment by Monotherapy Products, Q2 2011 22
Assessment by Route of Administration, Q2 2011 23
Assessment by Stage and Route of Administration, Q2 2011 24
Assessment by Molecule Type, Q2 2011 25
Assessment by Stage and Molecule Type, Q2 2011 26